Business Wire

THALES

Share
Eseye Selects Thales to Streamline IoT Deployments With Seamless Connectivity Management

Eseye, a global IoT connectivity solutions provider, has selected Thales to accelerate and simplify worldwide IoT deployment with a seamless connectivity solution. Thales pioneering solution enables Eseye to automatically connect IoT devices with the most appropriate profile the first time they are powered up and in-life. Thales Adaptive Connect (TAC) based on eSIM (embedded SIM) technology that drastically simplifies the management of IoT devices lifecycle. It is the first market-ready solution that eliminates the need to configure mobile subscriptions in the factory, or for technicians to visit them in the field.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228389495/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

@Thales

Eseye provides IoT cellular connectivity services worldwide, and TAC brings connectivity management of IoT devices remotely to make it far easier for its customers to roll-out and support major projects in areas such as: smart utilities, supply chains, logistics, and automotive. Indeed, any kind of IoT device can be deployed and connected in any region or country without being configured beforehand.

TAC is remotely managing the eSIM automatic configuration to provide the best local connectivity from its first usage and throughout its lifespan on the field. With Thales, Eseye can ensure they all connect to the preferred mobile network whenever it is needed. For example, deployed IoT devices can be switched to another mobile network remotely, over-the-air, at any time. The Thales solution fully complies with GSMA eSIM IoT standard SGP.32, ensuring security, reliability, and future proof capability for massive IoT use cases.

Thanks to the Thales connectivity offer for eSIM-based devices, Eseye will be able to operate and manage flexible, end-to-end connectivity from the factory to the field, and throughout the device lifecycle. Which means the entire operation, including manufacturing, logistics, and connectivity, is streamlined and simplified.

“Eseye are delighted to be partnering with Thales to take forward this leading-edge, innovative new IoT solution. Combining SGP.32 and SGP.41 support will ensure future IoT device deployments can deliver optimum efficiency and value to our customers. Not only do Enterprise customers get a completely future proofed eSIM platform, but it also enables maximum choice of either personalising devices for local mobile networks ahead of deployment or using TAC to do this for them in the field” said Adam Hayes, Chief Operating Officer at Eseye.

"Eseye is a dynamic partner with whom we have also worked on a Proof of Concept for customers interested in in-factory provisioning (IFPP) for their devices. This enables profiles to be securely provisioned during the device manufacturing process. For example, a blood sugar monitor device that has been configured at the factory will have a substantially longer battery life since there is no need for an in-field local profile download. This solution, which meets the latest market specifications (SGP.41), retains all of the benefits of an automatic and cost-effective connection to the preferred local network," said Guillaume Lafaix, VP of Connectivity Solutions and Embedded Products at Thales.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 77,000[1] employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

[1] Excluding the Transport business

PLEASE VISIT
Thales Group
Digital Identity & Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228389495/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release

The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye